|Mr. Christopher Schelling||Founder, Pres, CEO & Director||436k||N/A||1976|
|Mr. Harry S. Palmin||Chief Financial Officer||382.4k||N/A||1970|
|Mr. Jefferson E. Davis||Chief Bus. Officer||326.67k||N/A||1967|
|Ms. Tanya Hayden||Chief Operating Officer||N/A||N/A||N/A|
|Mr. John Michael Klopp||Chief Technical Officer||N/A||N/A||1975|
|Mr. Donald R. Joseph J.D.||Chief Legal Officer & Sec.||N/A||N/A||1954|
|Mr. Bernie Paul||Chief People Officer||N/A||N/A||1959|
|Mr. Matthew T. Seibt||Chief Commercial Officer||N/A||N/A||1971|
|Dr. Adrian Quartel FFPM, M.D.||Chief Medical Officer||N/A||N/A||1967|
|Mr. Jason Kneeland CPA||VP of Fin. & Controller||N/A||N/A||N/A|
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Acer Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.